Hemp « AGORACOM Small-cap Investor Relations Blog

Posts Tagged ‘Hemp’

Bougainville Venture’s $BOG.ca Oroville, WA Cultivation Facility Ready for Occupancy $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 1:02 PM on Thursday, September 27th, 2018

681747 5720 copy 2

Cultivation facility in Oroville, WA will be occupied by a Tier-3, I-502 tenant within the next weeks
The tenant is in the final process of obtaining approval of plans and issuance of permits from Okanogan County and Washington State Liquor Cannabis Board (WSLCB)

Vancouver, BC / September 27, 2018 – BOUGAINVILLE VENTURES INC. (“Bougainville” or the “Company”) (CSE: BOG), providing cannabis infrastructure and seed-to-sale services to I-502 tenant-growers, is pleased to announce that its cultivation facility in Oroville, WA will be occupied by a Tier-3, I-502 tenant within the next weeks. The tenant is in the final process of obtaining approval of plans and issuance of permits from Okanogan County and Washington State Liquor Cannabis Board (WSLCB).

Our Cultivation Facility

Our initial facility is situated on prime farmland in Oroville, WA with easy access to transportation, industrial infrastructure, power, water, gas, and courier services in the northern region of the Okanagan Valley.

The cultivation facility consists of 6 greenhouses providing a total of 30,000 sq. ft. of cultivation area. Three of the greenhouses are complete. Final construction of all 6 greenhouses is expected to be completed in February, 2019.

The Oroville facility is projected to produce in excess of 12,000 lbs. of high quality cannabis per annum upon completion of all the greenhouses.

CEO, Andy Jagpal Comments:

“Our Oroville facilities are now ready for our first tenant to take occupancy. We are also in the final stages of signing other I-502 tenants for this facility. In addition, we are in the process of acquiring new cultivation facilities in other cannabis-approved jurisdictions.”

About Bougainville Ventures, Inc.
Bougainville provides cannabis infrastructure and seed-to-sale services to I-502 tenant-growers leasing greenhouse facilities space and providing fully built-out, turnkey solutions and ancillary services including processing, cannabis expertise and marketing and sales resources. Greenhouse canopies provide a 50% saving in cultivation cost. Bougainville has 30,000 sq ft in near production in Oroville, WA.

For more information please visit: http://bougainvilleinc.com/

On behalf of the Board of Directors

BOUGAINVILLE VENTURES INC.

_____________________

Andy Jagpal, CEO and Director

For further information, please contact Andy Jagpal at [email protected] or 1-844-734-8420 ____________

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws, including statements regarding the Oroville, WA cultivation facility: statements pertaining to the ability of Bougainville Ventures Inc. (“BOG”); the anticipated economic potential of the property; the availability of capital and finance for BOG to execute its strategy going forward. Forward-looking statements are based on estimates and assumptions made by BOG in light of its experience and perception of current and expected future developments, as well as other factors that BOG believes are appropriate in the circumstances. Many factors could cause BOG’s results, performance or achievements to differ materially from those expressed or implied by the forward looking statements, including: discrepancies between actual and estimated results from exploration and development and operating risks, dependence on early exploration stage concessions; uninsurable risks; competition; regulatory restrictions, including environmental regulatory restrictions and liability; currency fluctuations; defective title to mineral claims or property and dependence on key employees. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Tags: #smallcapstocks, $TSXV, CSE, Hemp, Marijuana Stocks, MMJ, weed
Posted in All Recent Posts, Bougainville Ventures | Comments Off on Bougainville Venture’s $BOG.ca Oroville, WA Cultivation Facility Ready for Occupancy $CROP.ca $VP.ca NF.ca $MCOA

Tetra Bio-Pharma $TBP.ca Announces PPP002 Program Update Following Type B Meeting with U.S. FDA $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:02 AM on Thursday, September 27th, 2018

Announced that it conducted a Type B meeting with the United States Food and Drug Administration (FDA) for its dronabinolÂ AdVersa™Â mucoadhesive product, PPP002
The purpose of the meeting was to obtain confirmation of the eligibility of PPP002 for the 505(b)(2) NDA and the requirements for marketing approval

Shorter regulatory pathway confirmed by FDA and potential for Schedule 3 classification

ORLEANS, Ontario, Sept. 27, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it conducted a Type B meeting with the United States Food and Drug Administration (FDA) for its dronabinolÂ AdVersa™Â mucoadhesive product, PPP002. The purpose of the meeting was to obtain confirmation of the eligibility of PPP002 for the 505(b)(2) NDA and the requirements for marketing approval.

The FDA confirmed the eligibility of the 505(b)(2) regulatory pathway for the product PPP002 and that the efficacy and systemic safety would be supported by the corporationâ€™s proposed comparative bioavailability study and if successful Tetra could apply for FDA approval in Q1 2019, for Chemotherapy Induced Nausea and Vomiting as well as Anorexia associated with Weight Loss in Patients with AIDS. The FDA also provided feedback on the local safety requirements and the evaluation of the abuse potential of PPP002 for obtaining a Schedule III controlled substance classification.

“We are very pleased with the outcome of yesterdayâ€™s meeting with the U.S. FDA,â€ said Guy Chamberland, M.Sc., Ph.D., Interim Chief Executive Officer and CSO of Tetra Bio-Pharma. â€œThe FDA confirmed the shorter regulatory path to the market that Tetra had promised shareholders. In addition, the FDA also provided clear guidance on the safety and drug abuse data requirements for the new drug application. With this confirmation and guidance, Tetra can now complete the execution of the clinical program for PPP002 and, if successful, anticipates submitting a New Drug Application to commercialize PPP002 in Q1 2019.”

According to the International Agency for Research on Cancer1, the global chemotherapy-induced nausea and vomiting (CINV) market will reach a valuation of US$1.88 bn by 2020, an increase from its 2013 valuation of US$1.28 bn. Based on the expected improved safety profile of delayed release dronabinol, Tetra expects that AdVersa™ could gain significant market share within three (3) years of its launch in the USA.

Reducing Opioid Use
The opioid crisis is serious and growing throughout North America. Tetraâ€™s rich cannabinoid-derived product pipeline has the potential to play a significant role in opioid sparing, thus addressing a societal issue of critical proportion. Tetra expects to undertake a Phase II clinical trial using PPP002 up against an opioid to treat chronic pain.

AboutÂ Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of PPP002, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
Energi PR
Carol Levine
514-288-8500 ext. 226
[email protected]

Stephanie Engel
416-425-9143 ext. 209
[email protected]

Tags: #graphitestocks, #smallcapstocks, $TSXV, Hemp, MMJ
Posted in Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Announces PPP002 Program Update Following Type B Meeting with U.S. FDA $AERO $CBDS $CGRW $APH.ca $GBLX

INTERVIEW: Bougainville Ventures $BOG.ca Discusses Farmland to Greenhouse Conversion $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 12:18 PM on Tuesday, September 25th, 2018

Tags: #smallcapstocks, $TSXV, CSE, Hemp, Marijuana, MMJ
Posted in AGORACOM Via Satellite, All Recent Posts, Bougainville Ventures | Comments Off on INTERVIEW: Bougainville Ventures $BOG.ca Discusses Farmland to Greenhouse Conversion $CROP.ca $VP.ca NF.ca $MCOA

Tetra Bio-Pharma $TBP.ca Takes One Step Closer to the Commercialization of Cannabis Oil-Based Retail Products $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:00 AM on Monday, September 24th, 2018

Made significant progress in its clinical trial for PPP005 the cannabis oil-based capsules destined for the natural health products market
Tetra and its clinical research partner, SantÃ© Cannabis, announced that the clinical trial in non-cancer chronic pain patients will be completed later this autumn as promised

ORLEANS, Ontario, Sept. 24, 2018 – Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), has made significant progress in its clinical trial for PPP005 the cannabis oil-based capsules destined for the natural health products market.

Tetra and its clinical research partner, SantÃ© Cannabis, announced that the clinical trial in non-cancer chronic pain patients will be completed later this autumn as promised.Â This was the first clinical trial of its kind in evaluating the safety and efficacy of different doses and ratios of cannabis oils versus placebo. Â The study included a dose titration phase (gradually bringing patients to the required dose) allowing us to better understand the side effect profile of the oils as well as the development of tolerance to these effects. Â Thus far, no other company in the medical cannabis space has undertaken such an exhaustive study to understand the therapeutic benefits and side effects of a cannabis oil-based capsule.

Dr. Chamberland, interim CEO and CSO added, “We continue to deliver on our business model that provides for evidence-based research to support the usage of cannabis-derived products and provide the medical community with the data they have been demanding from this sector. The trial has already provided unique valuable clinical data on both safe and efficacious dose levels of CBD and THC-CBD oils.Â This data will allow Tetra to advance to the next phase of product development wherein the company is developing products for its commercial partner Genacol Corporation Canada, as well as food supplements for the retail market and finally, our capsules that we intend to use in the treatment of chronic and cancer related pain.Â Tetra has already established itself as a trailblazer in the natural health product segment with the announcement of our intention to launch a Hemp Energy Drink and we intend to build on that momentum.â€

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of PPP005, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
Energi PR
Carol Levine	Stephanie Engel
514-288-8500 ext. 226	416-425-9143 ext. 209
[email protected]	[email protected]

Tags: #smallcapstocks, $TSXV, CSE, Hemp, Marijuana, MMJ, weed
Posted in Featured, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Takes One Step Closer to the Commercialization of Cannabis Oil-Based Retail Products $AERO $CBDS $CGRW $APH.ca $GBLX

AGORACOM Welcomes North Bud Farms Inc. $NBUD.ca Focusing On Sustainable Low Cost, High Quality Cannabinoid Production

Posted by AGORACOM-JC at 8:43 AM on Friday, September 21st, 2018

WHY NORTH BUD FARMS INC?

Canadian regulatory door for CIP (Cannabinoid Infused Products) is opening in 2019
As shown in other legal jurisdictions (Colorado, Washington, Nevada, California)
Infused products sector has become the highest margin segment of the industry
Positioned to be a raw input producer for this space
Currently working with multiple food, beverage and science companies to provide safe standardized cannabinoid infused raw inputs for large scale GMP manufacturing of products

THE OPPORTUNITY

Acquired late stage ACMPR applicant GrowPros
MMP from Tetra Bio-Pharma (TSXV: TBP)
GrowPros MMP application was submitted in November 2014 and is currently in the â€˜Confirmation of Readinessâ€™ stage.
Phase 1 is located on 95 acres of agricultural farmland in Low, QuÃ©bec.
Option exists to acquire more land if needed
Facility will focus on GMP (higher production grade) pharma-grade cultivation and food-grade extracted inputs

LOCATION

SITE DETAILS: LOW COST INFRASTRUCTURE

POSITIONED FOR LEGALIZATION 2.0

First mover advantage often becomes first-mover disadvantage
Examples: AOL, Netscape, Yahoo, BlackBerry
Second mover advantage: clearer picture of market and competition
Examples: Google, Facebook, Amazon, Apple, NORTHBUD

STRATEGIC VERTICALS

Pharma Development

North Bud will focus on GMP standardized production to be used by our pharma commercialization partners i.e. Tetra Bio-Pharma We will focus on securing unique strains containing high amounts of specific cannabinoids not typically found in recreational cannabis.

Food Grade Inputs

- Using our licensed encapsulation technology we will
  engage existing food and beverage companies looking
  to develop product lines containing cannabis.

Tags: #smallcapstocks, $TSXV, Cannabinoid, CSE, Hemp, MMJ
Posted in AGORACOM Clients (New), All Recent Posts, North Bud Farms Inc | Comments Off on AGORACOM Welcomes North Bud Farms Inc. $NBUD.ca Focusing On Sustainable Low Cost, High Quality Cannabinoid Production

Tetra Bio-Pharma $TBP.ca Provides Extension to North Bud Farms $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:30 AM on Friday, August 3rd, 2018

Announced that the company has provided an extension to North Bud Farms Inc
Tetra and North Bud Farms Inc. are working diligently to finalize the transaction and to this end Tetra Bio-Pharma has agreed to provide an extension to North Bud Farms Inc

ORLEANS, Ontario, Aug. 03, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that the company has provided an extension to North Bud Farms Inc.Â Tetra and North Bud Farms Inc. are working diligently to finalize the transaction and to this end Tetra Bio-Pharma has agreed to provide an extension to North Bud Farms Inc. with regards to the final receipt of North Budâ€™s prospectusâ€™.Â As one of the closing conditions to the sale these documents must now be submitted by August 31, 2018.Â Upon final receipt of North Budâ€™s prospectus and meeting the requirements requested by the Ontario Securities Commission, Tetra will announce the record date and begin the process with the distribution of the dividend which must be finalized before listing the shares of North Bud Farms Inc.

AboutÂ Tetra Bio-Pharma

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

More information at:Â www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.

Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
[email protected]

Tags: #smallcapstocks, $TSXV, CBD, CSE, Hemp, MMJ
Posted in Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Provides Extension to North Bud Farms $AERO $CBDS $CGRW $APH.ca $GBLX

Marijuana Company of America $MCOA and Global Hemp Group $GHG.ca Provide Update on New Brunswick Hemp Project $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:40 AM on Wednesday, May 30th, 2018

Planting of the seeds on the first 77 acres will be completed this week
Remaining 48 acres will be seeded over the next two weeks, once the farmers receive soil test results for this acreage and are able to determine fertilizer requirements for this year’s cultivation

Escondido, California–(May 30, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to provide an update on its 125-acre industrial hemp project in northeast New Brunswick with joint venture partner Global Hemp Group Inc. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG).

The planting of the seeds on the first 77 acres will be completed this week. The remaining 48 acres will be seeded over the next two weeks, once the farmers receive soil test results for this acreage and are able to determine fertilizer requirements for this year’s cultivation.

The Department of Aquaculture Agriculture and Fisheries (DAAF) will also be conducting fertility trials on reserved plots at participating farms. DAAF will contribute the fertilizers to the project as part of these trials. The trials will be conducted at no cost to the project and are a clear indication of the collaborative relationship that has been established with DAAF.

In addition, there is an organic certification trial underway on an additional two-acre plot at the project. It will take three years to complete the organic certification process for this field. As part of the process, the plot will begin a three-year cultivation rotation of hemp, oats and a green manure crop to be defined at a later date. In three years this plot will produce certified organic CBD and organic oats, a crop with an excellent market.

Project managers are currently evaluating drying equipment that will be required to process the biomass after it is harvested. Drying will prepare the biomass for shipment to processors for extraction of the cannabinoids. Management is in discussions with a number of potential processing partners for this material. A final decision will be made in the coming weeks.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets andÂ opportunities in this segment mature and develop.

About Global Hemp Group Inc.
Global Hemp Group Inc. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG), is headquartered in Vancouver, British Columbia, Canada, with base operations in Montreal and Los Angeles. The Company is focused on a multi-phased strategy to build a strong presence in the industrial hemp industry in both Canada and the United States. The first phase of this strategy is to develop hemp cultivation with the objective of extracting cannabinoids (CBD, CBG, CBN & CBC) and creating a near term revenue stream that will allow the Company to expand and develop successive phases of the strategy. The second phase of the plan will focus on the development of value-added industrial hemp products utilizing the processing of the whole hemp plant, as envisioned in the Company’s Hemp Agro-Industrial Zone (HAIZ) strategy.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: #smallcapstocks, $TSXV, CSE, Hemp, MMJ
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks | Comments Off on Marijuana Company of America $MCOA and Global Hemp Group $GHG.ca Provide Update on New Brunswick Hemp Project $AERO $CBDS $CGRW $APH.ca $GBLX

Marijuana Company of America and Global Hemp Group Provide Update on CBD Farm Joint Venture in Scio, Oregon $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:38 AM on Tuesday, May 15th, 2018

Provides an update on their CBD hemp farming project in Scio, Oregon
Garden operations are well underway at the farm
Initial nursery and propagation rooms for clones have recently been expanded to an additional attached greenhouse
Team continues to produce clones for planting in the current season

ESCONDIDO, Calif., May 15, 2018Â â€“Â MARIJUANA COMPANY OF AMERICA INC.Â (â€œMCOAâ€ or the â€œCompanyâ€) (OTC:MCOA) and joint venture partner Global Hemp Group Inc. (CSE:GHG) (OTC:GBHPF) (FRANKFURT:GHG) (the â€œPartnersâ€) are pleased to provide an update on their CBD hemp farming project in Scio, Oregon (the â€œProjectâ€).

Garden operations are well underway at the farm. The initial nursery and propagation rooms for clones have recently been expanded to an additional attached greenhouse as the team continues to produce clones for planting in the current season. In order to maximize planting density, an additional 20,000 high yielding CBD hemp clones are being purchased and will be delivered before the end of May to meet the targeted planting schedule of early June.

Five additional greenhouses have now been purchased for the project. The first two 30ft. x 120ft greenhouses are currently being installed and will provide an additional 7,200 sq. ft. of greenhouse space for the project. The three remaining 42ft x 96ft greenhouses will begin installation before the end of May. When installed, these additional greenhouses will increase greenhouse space by a further 12,096 sq. ft., for a total of 19,296 active greenhouse space.

The team will be planting the clones on the first 35 acres at the farm. They will be planted â€œorchard styleâ€, 4 to 5 feet on center, with rows 5 feet apart to provide space for each plant to receive sufficient sunlight, water and nutrients, and mature to maximum size to produce the highest CBD yield possible upon harvest.

The Scio farm will employ both traditional outdoor orchard style cultivation and perpetual harvest in greenhouses. The Partners are currently evaluating additional greenhouse technologies for expansion of indoor cultivation space to augment its perpetual harvest model square footage. This dual strategy will optimize revenue generation throughout the year to minimize the impact of single crop harvesting in October when most other hemp CBD farms harvest and typically drive prices down. Market prices tend to climb throughout the year as less biomass is available for processing and distribution, as is occurring with current market prices. Starting in August, it is expected that full spectrum CBD oil will be in tight supply and prices will continue to climb until after the October 2018 harvest season is processed.

The team is in the process of ordering the required equipment to facilitate farm operations from planting through harvesting, drying and storage.

In addition, the Partners are currently evaluating a field analytics software application to be employed for data collection and analysis to optimize farming operations. The software will be used to evaluate the three cultivation methods being employed by the Partners in 2018; high yielding CBD cultivars grown orchard style outdoors in Scio, Oregon, perpetual harvest in greenhouses also at Scio, and traditional dense field cropping with lower yielding CBD cultivars in New Brunswick, Canada.Â Results will assist the team in determining optimal yield per acre for future expansion of acreage in both the United States and Canada.

“Our evolving project in Scio, Oregon highlights the quality of the team in place as they continue to lean on their many years of experience cultivating hemp.Â Activities such as these will help to secure the raw oil that we will need for our hempSMART brand of CBD infused products,” says Donald Steinberg, CEO of Marijuana Company of America.Â See our products at www.hempsmart.com

â€œThe Scio, Oregon high yielding CBD hemp project is something that we have been working on putting together most of this year. Itâ€™s great to see that the project is now officially underway, and we look forward to sharing pictures and results of the operation as we go forward,â€ stated Charlie Larsen, President of Global Hemp Group.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name â€œhempSMART™â€, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets andÂ opportunities in this segment mature and develop.

About Global Hemp Group Inc.
Global Hemp Group Inc., is headquartered in Vancouver, BC, Canada, with base operations in Montreal and Los Angeles. The Company is focused on a multi-phased strategy to build a strong presence in the industrial hemp industry in both Canada and the United States. The first phase of this strategy is to develop hemp cultivation with the objective of extracting cannabinoids (CBD, CBG, CBN & CBC) and creating a near term revenue stream that will allow the Company to expand and develop successive phases of the strategy. The second phase of the plan will focus on the development of value-added industrial hemp products utilizing the processing of the whole hemp plant, as envisioned in the Companyâ€™s Hemp Agro-Industrial Zone (HAIZ) strategy.

Tags: #smallcapstocks, $TSXV, CBD, CSE, Hemp, MMJ
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks | Comments Off on Marijuana Company of America and Global Hemp Group Provide Update on CBD Farm Joint Venture in Scio, Oregon $AERO $CBDS $CGRW $APH.ca $GBLX

Namaste $N.ca Announces Updates to NamasteMD Patient Acquisition Portal and Appointment of Baran Dilaver as Interim COO $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 9:00 AM on Monday, May 14th, 2018

Announced the integration of several critical updates to the Companyâ€™s online patient acquisition tool, NamasteMD Inc.
Company’s revolutionary mobile app, which is available on desktop, Apple IOS and Android devices, has allowed Namaste to accelerate patient growth at a rate that exceeds any industry peers and at significantly lower cost per patient

VANCOUVER, British Columbia, May 14, 2018 – Namaste Technologies Inc. (â€œNamasteâ€ or the â€œCompanyâ€) (TSXV:N) (FRANKFURT:M5BQ) (OTCMKTS:NXTTF) is pleased to announce the integration of several critical updates to the Companyâ€™s online patient acquisition tool, NamasteMD Inc. (â€œNamasteMDâ€). NamasteMD, which is the Company’s revolutionary mobile app, which is available on desktop, Apple IOS and Android devices, has allowed Namaste to accelerate patient growth at a rate that exceeds any industry peers and at significantly lower cost per patient. NamasteMD is presently ranked as the #2 Medical application in the Canadian Apple Store. NamasteMD provides a simple digital platform for patients to acquire medical cannabis documentation from the comfort of their home. Since its initial launch, the Company has acquired over 2,000 patients exclusively through organic growth without any paid advertising. The Company believes that the recent updates to the app will allow Namaste to fully deploy its marketing strategy and accelerate growth in what the Company believes will soon be Canadaâ€™s largest database of medical cannabis patients.

With this release patients now have a more streamlined and reliable video experience, enabled by our trusted partner Twilio. This release also includes stability and performance improvements, including a fix for a bug that was preventing a small percentage of our users from logging in. The Company will focus on continued updates to increase the acceleration rate of its patient database through organic and paid advertising channels.

Additionally, the Company would like to announce that co-founder Kory Zelickson is transferring roles to become Vice President of Business Development and Investor Relations, and that Baran Dilaver will be appointed as the Companyâ€™s interim Chief Operating Officer. With the Companyâ€™s rapid expansion, Kory will focus on the growth of the Company in the areas of business development, strategic partnership and in investor relations and hand-off operations to Baran Dilaver, who has many years of experience in operations. This strategic decision will allow both Kory and Baran to excel in each of their respective areas to further propel the growth of the Company. Mr. Baran Dilaver has extensive experience in running companies and for the past three months, Baran Dilaver has been focused on improving Namasteâ€™s operations and organizing its various business divisions. The Company welcomes Baran in joining as Interim COO and believes that these changes will provide further value to its shareholders. Upon his appointment, Baran Dilaver commented: â€œI am thrilled to have such a critical role in shaping Namasteâ€™s future, and I am in a great position to lead the recruitment of a world class COO to hand over some of the initiatives I started here with the operations and finance teams.â€

About Baran Dilaver

BaranÂ is an entrepreneur, creator, and an accomplished executive.Â Â He launched several well-known brands worldwide and conceived and developed over 80 products.Â Â BaranÂ is the founder of FutureScape, a technology focused product design and branding company andÂ recently, as the COO and CMO at Firefly Vapor, he created and implemented business strategies that established Firefly as one of the most admired brands in the cannabis industry.Â Â Prior to Firefly,Â Baran Dilaver was the CEO of United Brands, a leading food technology company based out of San Francisco.Â He is a speaker in conferences like Tech Open Air Berlin, CannaTech, and European Communications Summit.Â Â He was a scholar athlete at UC Berkeley and studiedÂ Economics.Â Â He loves kitesurfing and snowboarding around the world and building large-scale art installations at Burning Man.

Management Commentary

Sean Dollinger,Â President and CEO of Namaste comments;Â â€œWeâ€™re very pleased to have had major updates approved to the NamasteMD platform. I believe that NamasteMD provides the Company with a competitive edge in being the first company in Canada to fully digitize patient acquisition. At a cost of only $60 per patient, Namaste is able to acquire patients at a much lower cost than our peers who require the use of physical clinics or doctors to acquire patients. In a very short period of time we have managed to acquire over 2,000 patients organically with zero spend on marketing or promotion. At this point of the business cycle we now feel that the platform is ready for full launch and anticipate an even more significant acceleration of growth over the next several months through a strategic marketing campaign.

Additionally, Iâ€™m very pleased to have Kory focus on his areas of expertise in business development and investor communications where he brings major value to the Company. We have been continuously growing as a company and Kory has filled in as COO, but we have now decided to have each team member focus exclusively in their areas of expertise. The investor relations and business development role is very important to the Company and Kory is best fit for this role. We are also very pleased to be bringing on Baran Dilaver as interim COO who has many years of experience in the industry and as someone who has developed a deep level of understanding of Namasteâ€™s global operations. Moving forward we are in a prime position to leverage an amazing management team and innovative technology to advance as a global leader in all things cannabis.â€

About Namaste Technologies Inc.

Namaste Technologies is a global leader in the sale of medical cannabis consumption devices. Namaste has nine offices with multiple distribution centers around the globe and operates over 30 websites under various brands. Namaste has developed innovative technology platforms including NamasteMD.com, Canada’s first ACMPR compliant telemedicine application. The company is focused on patient acquisition through NamasteMD and intendsÂ on building Canada’s largest database of medical cannabis patients. The company’s subsidiary, CannMart Inc. is an ACMPR Licensed Producer with a “sales-only” license, whereby the company will offer a large variety of medical cannabis sourced from domestic and international producers. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to itsÂ shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

â€œSean Dollingerâ€

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The TSXV has neither reviewed nor approved the contents of this press release.

Tags: #smallcapstocks, $TSXV, CBD, CSE, Hemp, MMJ, Vapes, Vaping
Posted in All Recent Posts, Namaste Technologies Inc. | Comments Off on Namaste $N.ca Announces Updates to NamasteMD Patient Acquisition Portal and Appointment of Baran Dilaver as Interim COO $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Tetra BioPharma $TBP.ca Signs Second Commercialization Deal with Azevedos Industria Farmaceutica, S.A. for the Lead RX product PPP001 $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:24 AM on Friday, May 4th, 2018

Tetra Bio-Pharma Inc. and Azevedos IndÃºstria FarmacÃªutica, S.A. announced that they have signed a binding term sheet for the marketing and distribution of PPP001 in Portugal
Binding term sheet will pave the way towards signing a Definitive Distribution Agreement.
Tetra is eligible to receive an upfront payment, milestone payments and will be paid a share of the profits generated by the sales of PPP001 in Portugal.
Azevedos will also be responsible for registering the product, as well as all marketing and distribution in Portugal

OTTAWA, May 04, 2018 – Tetra Bio-Pharma Inc. (â€œTetraâ€ or the â€œCompanyâ€) (TSX-V:TBP) (OTCQB:TBPMF), and Azevedos IndÃºstria FarmacÃªutica, S.A. announced that they have signed a binding term sheet for the marketing and distribution of PPP001 in Portugal. This binding term sheet will pave the way towards signing a Definitive Distribution Agreement.

Tetra is eligible to receive an upfront payment, milestone payments and will be paid a share of the profits generated by the sales of PPP001 in Portugal. Azevedos will also be responsible for registering the product, as well as all marketing and distribution in Portugal.

â€œWe are honored to partner with Azevedos, a company established in 1775, rich in tradition, and a major player in the Portuguese pharmaceutical market. This Partnership deal provides Tetra with its foray into the European market.â€ stated Dr. Guy Chamberland M.Sc., Ph.D., Interim CEO and Chief Scientific Officer.

â€œThese partnerships are very important for Azevedos IndÃºstria FarmacÃªutica and mean that international entities recognize our history, values, work and our technology know-how. Although having a long past, Azevedos is a pharmaceutical company turned to the future and focused on new challengesâ€, says Thebar Miranda, CEO of Azevedos IndÃºstria Farmaceutica, S.A.

About PPP001Â
On April 4, 2018, Tetra officially started the Phase 3 trial for PPP001 indicated for terminal stage cancer patients with a goal to improving the quality of life of these patients as well as minimizing their pain. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.

About Azevedos IndÃºstria FarmacÃªutica, S.A
Azevedos Group is a two-century Portuguese pharmaceutical brand, whose wide scope of activity ranges from development to distribution, leading manufacturing and exports to more than 60 regulated countries worldwide. Azevedos owns more than 300 MAs for the most relevant therapeutic areas covering all technology forms manufactured at its state of the art plant holding the most recognized certifications.

About Tetra Bio-Pharma: Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. Tetra Bio-Pharma is currently developing a pipeline of five cannabinoid-based products using different delivery systems such as smokable pellets, oral tablets, eye drops and topical ointments.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact:
Tetra Bio-Pharma Inc.
Dr Guy Chamberland, interim CEO and CSO
[email protected]
514-220-9225

Robert (Bob) Bechard, MBA, MSc., BA,
Vice-President Finance and Business Development
[email protected]
514-817-2514

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: 1 514-840-7990 M: 1 514-232-1556

Tags: #smallcapstocks, $TSXV, CSE, Hemp, MMJ
Posted in All Recent Posts | Comments Off on Tetra BioPharma $TBP.ca Signs Second Commercialization Deal with Azevedos Industria Farmaceutica, S.A. for the Lead RX product PPP001 $AERO $CBDS $CGRW $APH.ca $GBLX

Posts Tagged ‘Hemp’

Categories